Eph receptor and ephrin function in breast, gut, and skin epithelia

Bethany E Perez White1 and Spiro Getsios1,2,*

1Departments of Dermatology; Northwestern University; Chicago, IL USA; 2Cell and Molecular Biology; Feinberg School of Medicine; Northwestern University; Chicago, IL USA

Keywords: Breast, cell-cell, Eph receptor, ephrin, epithelial, intestine, receptor tyrosine kinase, skin, stem cell

Abbreviations: ADAM, a disintegrin and metalloprotease; Apc, adenomatous polyposis coli; Eph, erythropoietin-producing hepatocellular; ER, estrogen receptor; Erk, extracellular signal-regulated kinase; GEF, guanine nucleotide exchange factor; GPI, glycosylphosphatidylinositol; HER2, human epidermal growth factor receptor 2; HGF, hepatocyte growth factor; IBD, inflammatory bowel disease; KLF, Krüppel-like factor; MAPK, mitogen-activated protein kinase; MMTV-LTR, mouse mammary tumor virus-long terminal repeat; MT1-MMP, membrane-type 1 matrix metalloproteinase; PDZ, postsynaptic density protein 95, discs large 1, and zonula occludens-1; PTP, protein tyrosine phosphatase; RTK, receptor tyrosine kinase; SH2, Src homology 2; SHIP2, SH2 inositol phosphate 2; SLAP, Src-like adaptor protein; TCF, T-cell specific transcription factor; TEB, terminal end bud; TNFα, tumor necrosis factor α.

Epithelial cells are tightly coupled together through specialized intercellular junctions, including adherens junctions, desmosomes, tight junctions, and gap junctions. A growing body of evidence suggests epithelial cells also directly exchange information at cell-cell contacts via the Eph family of receptor tyrosine kinases and their membrane-associated ephrin ligands. Ligand-dependent and -independent signaling via Eph receptors as well as reverse signaling through ephrins impact epithelial tissue homeostasis by organizing stem cell compartments and regulating cell proliferation, migration, adhesion, differentiation, and survival. This review focuses on breast, gut, and skin epithelia as representative examples for how Eph receptors and ephrins modulate epithelial cell responses in a context-dependent manner. Abnormal Eph receptor and ephrin signaling is implicated in a variety of epithelial diseases raising the intriguing possibility that this cell-cell communication pathway can be therapeutically harnessed to normalize epithelial function in pathological settings like cancer or chronic inflammation.

Introduction

Erythropoietin-producing hepatocellular (Eph) receptor tyrosine kinases (RTKs) are activated upon binding to their membrane-associated ephrin ligands. This large family of RTKs is subdivided into 2 subclasses, EphA (1–8, 10) and EphB (1–4, 6) receptors based on amino acid sequence homology and relative binding affinities to glycosylphosphatidylinositol (GPI)-linked ephrin-A (1–5) or transmembrane ephrin-B (1–3) ligands. There is extensive promiscuity for ligand binding within receptor subclasses and more limited interaction between receptors and ligands in different subclasses.1–3 While EphA and EphB receptors generally share conserved extracellular and cytoplasmic subdomain structure, the ephrin-A and -B ligand subfamilies differ substantially in the C-terminal region and mechanism of membrane-anchorage (Fig. 1). These molecular and biochemical features confer a considerable degree of complexity in the organization and function of Eph receptor and ephrin signaling complexes.

As both receptors and ligands are membrane-bound, the interaction of Eph receptors and ephrins is commonly thought to occur at cell-cell contacts. However, this is not an absolute requirement for Eph receptor signaling as ligand-independent functions for these RTKs have been described and there is evidence that EphA receptors can be activated by soluble ephrin-A ligands present in the microenvironment.4,5 Ligand binding to Eph receptors at cell-cell contacts rapidly leads to the formation of higher order signaling clusters required for robust kinase activation, effector molecule recruitment, and transmission of a variety of downstream signaling cascades.6,7 Contact-dependent signaling is evident where there is complementary expression of Eph receptor and ephrin in distinct cell types but there also appears to be a major role for Eph receptor signaling complexes in cell types where there is overlapping expression of receptor and ligand, particularly in epithelial tissues.

The signaling cascades induced by Eph receptors and ephrins are important for a wide range of cellular processes that govern embryonic development and tissue patterning. Frequently, this involves altered cell-cell adhesion resulting in either cell attraction or repulsion that occurs in a context-dependent manner.8 Arguably, less is known about the precise Eph receptor-mediated transmission of membrane signals from the cytoplasm into the nucleus to impact gene expression compared to other RTKs.
Another unique property of Eph receptor signaling is that it is bidirectional in character, with ligand-mediated activation of Eph receptor leading to forward signaling while reverse signaling is elicited in ephrin-expressing cells. Eph receptor and ephrin signaling has been shown to play a prominent role during embryogenesis, but a growing body of evidence indicates that adult epithelial tissues are another major site for Eph receptor and ephrin ligand action.\textsuperscript{9-14}

Epithelial tissues line body surfaces and cavities. They are composed of single (simple) or multiple (stratified) layers of epithelial cells that are tightly anchored to the underlying basement membrane and one another via specialized junctional complexes; these include integrin-based adhesion complexes for cell-extracellular matrix anchorage points while adherens junctions, desmosomes, tight junctions, and gap junctions are found at cell-cell contacts.\textsuperscript{8} Eph receptors are not simply activated at cell-cell contact sites but also negatively or positively regulate these junctional complexes in a manner that depends on the character of the receptor involved, the relative abundance of ligand within the tissue, and the cell type in question.\textsuperscript{15,16} As such, Eph receptor signaling can modulate epithelial tissue remodeling, integrity, and barrier function.

Homeostasis maintains cellular stability and tissue function. In actively regenerating epithelial tissues, homeostasis is maintained, in part, by the balance of cell proliferation and cell death. This balance relies on the presence of epithelial stem cells, which are found in distinct compartments within the tissue termed niches. Eph receptor and ephrin signaling has emerged as a major regulator of epithelial tissue homeostasis by regulating the organization of stem cell compartments as well as modulating the ability of progenitor cells to proliferate or differentiate.\textsuperscript{17-19} Moreover, aberrant expression or activation of Eph receptors and ephrins is believed to contribute to malignant or pathologic states in epithelial tissues.\textsuperscript{9-12,14,20} This review focuses on the role of Eph receptor and ephrin signaling in epithelial tissues that undergo extensive regeneration and remodeling in adults, including those present in the breast, gastrointestinal tract, and skin.

**Organization of Eph Receptors and Ephrins in Epithelial Cells**

Activation of Eph receptor and ephrin signaling complexes

Eph receptor signaling is distinct from that of other RTKs as receptor-ligand interactions rely on proximity between adjacent cell membranes and ephrin binding induces bi-directional signaling within the receptor-and ligand-bearing cell. The apposition of plasma membranes between adjacent epithelial cells facilitates Eph receptor and ephrin signaling but the precise molecular organization of these cell surface signaling complexes remains to be clearly elucidated in most epithelial tissues, particularly when receptor and ligand are co-expressed.

In the case of forward signaling, extracellular interactions between ephrins and Eph receptors initiate a conformational change in the receptor cytoplasmic domain that releases antiinhibitory interactions, triggering kinase activity and recruitment of Src homology 2 (SH2) domain- and phosphotyrosine binding domain-containing proteins to the cell surface.\textsuperscript{21-27} Eph receptors also undergo clustering within the plasma membrane upon ligand binding in a manner that is stabilized by additional interactions with other ectodomain and cytodomain regions present on the receptor.\textsuperscript{6,28-30} The size of the receptor signaling clusters can vary depending on the mobility of ephrins on adjacent membranes and the cell type in question.\textsuperscript{31} Eph receptor can also form hetero-oligomer clusters with members of a different receptor subclass.\textsuperscript{32,33} Taken together, this allows for a considerable degree of complexity in the molecular organization of Eph receptor signaling complexes in epithelial tissues where multiple family members are expressed.

Coincident with Eph receptor binding, reverse signaling is initiated in ephrin-expressing cells. In particular, ephrin-B ligands can cluster in the plasma membrane and are phosphorylated by Src family kinases in their cytoplasmic domain after binding Eph receptors via their ectodomains.\textsuperscript{34-36} This phosphorylation of tyrosine residues facilitates interaction with SH2 domain-containing proteins but the ephrin-B cytoplasmic tail also interacts
with effector proteins via serine phosphorylation-dependent events and its PDZ (postsynaptic density protein 95, discs large 1, and zonula occludens-1) binding motif.\textsuperscript{37-40} Although lacking a cytoplasmic domain, GPI-linked ephrin-A ligands modulate intercellular signaling, particularly in the Src family kinase pathway, likely through clustering within lipid raft membrane domains.\textsuperscript{41} As outlined below, there is evidence for forward and reverse signaling via both subclasses of Eph receptors and ephrins in epithelial tissues.

**Attenuation of Eph receptor signaling complexes**

Eph receptors are stabilized and become activated at cell-cell contacts but the fate of these ligand-bound receptors is not fully understood in epithelial cells. In general, attenuation of Eph receptor signaling occurs through mechanisms common to many RTKs including phosphatase-dependent dephosphorylation, proteolytic cleavage, or endocytosis.

Eph receptors can be negatively regulated by multiple protein tyrosine phosphatases (PTP) in epithelial cells. For example, PTP1B limited EphA3 kinase activity leading to the attenuation of ephrin-induced contraction of the actin cytoskeleton in human kidney epithelial cells.\textsuperscript{42} Similarly, low molecular weight-PTP negatively regulated EphA2 to prevent subsequent downregulation of mitogen-activated protein kinase (MAPK) signaling in prostate epithelial carcinoma cells.\textsuperscript{43} Elevated PTP activity in epithelial cells may also stabilize Eph receptors at the epithelial cell surface via mechanisms that have yet to be resolved.

Upon ligand binding, Eph receptors can undergo a specialized form of internalization termed transendocytosis; this involves collective internalization of Eph receptor and ephrin complexes into the same cell. A clathrin-dependent internalization mechanism that relied on Rac signaling and Rho-guanine nucleotide exchange factor (GEF) Tiam1 binding to the EphA receptor juxtamembrane domain has been described in pancreatic carcinoma and kidney epithelial cells.\textsuperscript{44,45} Conversely, EphA2 was stabilized at the cell surface in invasive breast cancer cells by SH2-containing 5'-inositol phosphatase 2 (SHIP2) through sterile α motif domain interactions between the respective proteins.\textsuperscript{46} EphA2 stabilization was dependent on SHIP2-mediated dephosphorylation of PI3, which inhibits Rac1-GTPase-dependent endocytosis. Thus, Eph receptor recruitment of signaling effectors that differentially regulate Rac1 can determine receptor fate at the epithelial cell surface.

While receptor endocytosis eliminates Eph signaling at cell-cell contacts, internalized Eph receptor complexes continue to signal inside the cell. For example, EphA2 in early endosomes exhibited high tyrosine phosphorylation content and a fraction of internalized EphA2 recycled back to the plasma membrane where it presumably engaged new ligand.\textsuperscript{47} Investigation into the regulation of Eph receptor endosomal trafficking events will likely reveal factors important for receptor recycling or degradation pathways that influence signaling persistence in epithelial cells.

Eph receptor signaling complexes can also be internalized following protease-mediated cleavage of ephrins or the receptor. For example, EphA3 bound by ephrin-A5 was internalized upon proteolytic cleavage of the ligand by a disintegrin and metalloprotease 10 (ADAM10) in kidney epithelial cells and EphA2 was cleaved by membrane-type 1 matrix metalloproteinase (MT1-MMP) in breast carcinoma cell lines.\textsuperscript{48} Ubiquitin-mediated degradation provides another pathway to attenuate Eph receptor signaling in epithelial cells. In particular, ligand-dependent degradation of EphA receptors is mediated through interaction with c-Cbl resulting in receptor ubiquitination.\textsuperscript{44,49,50} While c-Cbl-mediated ubiquitination led to EphA receptor degradation, this process can be inhibited by binding to Odin, a member of the Ank family of ankyrin-rich repeat proteins, resulting in prolonged receptor signaling.\textsuperscript{51,52} Another route of EphA2 degradation has been shown to be dependent on the Src-like adaptor protein (SLAP). SLAP negatively regulated EphA2 signaling throughSH2-mediated binding to a Src-phosphorylated tyrosine site in the EphA2 tail.\textsuperscript{53} The subsequent degradation of EphA2 was dependent on the ubiquitination protein UBE4A. Overall, SLAP exerted tumor suppressive properties in colorectal cancer cells by attenuating EphA2 signaling through receptor destabilization, ubiquitin-dependent proteasomal degradation, and downstream attenuation of Akt signaling.\textsuperscript{53} Collectively, these findings indicate multiple modes of action converge to limit Eph receptor signaling events at epithelial cell-cell contacts.

**Eph Receptors and Ephrins in Breast Epithelium**

Eph receptor and ephrin expression in the mammary gland

The simple, cuboidal epithelium lining the ducts of the mammary gland undergoes repeated cycles of expansion and regression in response to changes in hormone levels. These epithelial remodeling events rely on stem cells located throughout the epithelial ductal tree giving rise to myoepithelial and luminal cell lineages that populate the mammary gland.\textsuperscript{54} Multiple Eph receptors and ephrins are expressed in various breast epithelial cell compartments. For example, EphB4 and ephrin-B2 are found in the myoepithelium and luminal epithelium, respectively, while EphA2 is concentrated in terminal end buds (TEBs) (Fig. 2).\textsuperscript{55,57} The spatiotemporal expression pattern of Eph receptors and ephrins is important for breast epithelial tissue morphogenesis and function.

Eph receptor gene expression in breast epithelial cell compartments is partially dependent on hormone levels. An inverse correlation between estrogen receptor (ER) and EphA2 levels was found in nontransformed and breast carcinoma cells with estrogen treatment leading to a reduction in EphA2.\textsuperscript{58,59} In contrast, EphB4 expression was lost in ovariectomized mice and could be restored by exogenous administration of estrogen. This is consistent with the finding that EphB4 expression in myoepithelial cells is tightly regulated during the estrous cycle of mice.\textsuperscript{57,60} In turn, EphB4 was shown to modulate ER expression and activity in breast cancer cell lines, suggesting a feedback loop between Eph receptor activity and hormonal signaling pathways.\textsuperscript{61} The hormone-dependent action on Eph receptors is particularly relevant for mammary epithelium remodeling but may also impact non-reproductive tissues where gonadal steroid receptors are expressed, including the skin and gut.\textsuperscript{62,63}
Eph receptor and ephrin function in mammary gland development and homeostasis

Mammary gland expansion and regression are hormone-dependent processes mediated by a variety of signaling factors, including Eph receptors and ephrins. The most dynamic structures in the mammary gland are TEBs as they undergo branching morphogenesis to form extensive ductal networks in response to hormones in preparation for lactation. EphA2 expression is enriched in TEBs compared to ducts. EphB2 and EphB3 are important for maintenance of stem, progenitor and Paneth cells in the crypts. In the villi, ephrin-B1 and ephrin-B2 maintain the segregation of differentiated cells in the upper regions from precursor cells in the lower regions. Given the key role of Eph receptor and ephrin signaling in proper mammary gland morphogenesis, it is not surprising that these proteins have been associated with malignant breast phenotypes. For example, increased EphA2 expression has been found in aggressive breast cancers and was significantly correlated with decreased overall survival and invasive ductal carcinoma. Although breast ductal carcinomas express EphA2 and ephrin-A1, ligand expression is reduced in corresponding lymph node metastases. Breast carcinoma cell line invasiveness also correlated with a loss of Ephrin-A1 and mislocalization of EphA2 in the cytoplasm. Furthermore, ectopic expression of EphA2 was sufficient to transform normal breast epithelial cells in a manner that could be reverted by exogenous delivery of ephrin-A1. Collectively, these data indicate that EphA2 functions in a ligand-independent manner to promote breast cancer progression and metastasis but this RTK can subsequently normalize breast cancer phenotypes once re-engaged by ephrin-A ligand.

Eph receptor and ephrin signaling in breast cancer

Ephrin-B2 reverse signaling may account for this phenotype as a signaling-deficient mutant of ephrin-B2 lacking its cytoplasmic domain disrupted mammary epithelial cell polarity apparent by mislocalization of the apical junction complex proteins, Par-3 and zonula occludens-1. Ultimately, the loss of ephrin-B2-dependent polarity disrupted the breast epithelial stem cell niche and TEB organization by increasing progenitor cell proliferation and altering differentiation. EphB4 is predominantly expressed in the myoepithelial cells lining the outside of the ductal luminal epithelium. Ectopic EphB4 expression in breast luminal epithelial cells interfered with differentiation in the mammary epithelial tree by increasing luminal and progenitor cell populations. Collectively, these data suggest that spatial regulation of Eph receptor and ephrin expression is critical for signaling events that control the organization of mammary gland epithelial tissue compartments.

EphB receptors and ephrin-B ligands also play a major role in mammary epithelial tissue homeostasis. In particular, ephrin-B2 has been implicated in the maintenance of mammary epithelial stem cell compartments through control of differentiation. Conditional deletion of ephrin-B2 in the mammary epithelium of lactating mice led to a loss of glandular architecture and tissue integrity. Moreover, ephrin-B2-deficient alveolar epithelial cells exhibited impaired cell-cell adhesion with reduced levels of E-cadherin and increased β-catenin in the cytoplasm and nucleus.

Given the role of EphA2 in breast cancer, it may also be related to its role in modulating cell-cell adhesion complexes. For example, EphA2 expression is enriched in TEBs compared to ducts. EphA2 was required for proliferation and hepatocyte growth factor (HGF)-induced branching morphogenesis as post-pubertal mice lacking this receptor exhibited reduced ductal penetration into the fat pad, with a loss of ephrin-A1 and mislocalization of EphA2 in the cytoplasm. Therefore, ectopic expression of EphA2 was sufficient to transform normal breast epithelial cells in a manner that could be reverted by exogenous delivery of ephrin-A1. Collectively, these data indicate that EphA2 functions in a ligand-independent manner to promote breast cancer progression and metastasis but this RTK can subsequently normalize breast cancer phenotypes once re-engaged by ephrin-A ligand.

Perhaps underlying its association with aggressive breast cancers, EphA2 induced an estrogen-independent and tamoxifen-resistant growth phenotype in breast cancer cell lines that maintain expression of ER. In addition, EphA2 conferred resistance to therapy targeting oncogenic human epidermal growth factor receptor 2 (HER2) in breast cancer cells and xenograft tumors. Thus, EphA2 exhibits extensive cross-talk with other receptor-mediated signaling pathways to impact breast epithelial tumorigenesis.

The contribution of EphA2 in breast cancer may also be related to its role in modulating cell-cell adhesion complexes. For example, EphA2 expression is enriched in TEBs compared to ducts. EphA2 was required for proliferation and hepatocyte growth factor (HGF)-induced branching morphogenesis as post-pubertal mice lacking this receptor exhibited reduced ductal penetration into the fat pad, with a loss of ephrin-A1 and mislocalization of EphA2 in the cytoplasm. Therefore, ectopic expression of EphA2 was sufficient to transform normal breast epithelial cells in a manner that could be reverted by exogenous delivery of ephrin-A1. Collectively, these data indicate that EphA2 functions in a ligand-independent manner to promote breast cancer progression and metastasis but this RTK can subsequently normalize breast cancer phenotypes once re-engaged by ephrin-A ligand.

Perhaps underlying its association with aggressive breast cancers, EphA2 induced an estrogen-independent and tamoxifen-resistant growth phenotype in breast cancer cell lines that maintain expression of ER. In addition, EphA2 conferred resistance to therapy targeting oncogenic human epidermal growth factor receptor 2 (HER2) in breast cancer cells and xenograft tumors. Thus, EphA2 exhibits extensive cross-talk with other receptor-mediated signaling pathways to impact breast epithelial tumorigenesis.

The contribution of EphA2 in breast cancer may also be related to its role in modulating cell-cell adhesion complexes. For example, EphA2 expression is enriched in TEBs compared to ducts. EphA2 was required for proliferation and hepatocyte growth factor (HGF)-induced branching morphogenesis as post-pubertal mice lacking this receptor exhibited reduced ductal penetration into the fat pad, with a loss of ephrin-A1 and mislocalization of EphA2 in the cytoplasm. Therefore, ectopic expression of EphA2 was sufficient to transform normal breast epithelial cells in a manner that could be reverted by exogenous delivery of ephrin-A1. Collectively, these data indicate that EphA2 functions in a ligand-independent manner to promote breast cancer progression and metastasis but this RTK can subsequently normalize breast cancer phenotypes once re-engaged by ephrin-A ligand.
example, EphA2 was concentrated in the cytoplasm of invasive breast cancer cell lines in association with reduced E-cadherin levels. Silencing of EphA2 normalized E-cadherin-mediated adhesion in these breast cancer cells. Similarly, EphA2 overexpression was capable of disrupting adherens junctions through a RhoA-mediated mechanism in breast epithelial cells but, in this case, without altering adherens junction protein or phosphorylation levels. Since a cytoplasmic truncation EphA2 mutant lacking the C-terminal tail region did not disrupt cell-cell adhesion, this study suggested a direct role for EphA2 downstream signaling events that lead to adherens junction dissolution.

EphA2 can also regulate signaling pathways that alter the organization of the actin cytoskeleton to impact cell motility. For example, ephexin4 is a GEF that activated RhoG-induced chemotaxis of breast cancer cells downstream of EphA2. Activated RhoG recruited its effectors ELMO2 and Dock4 into a complex with EphA2 at the leading edges of migrating breast cancer cells. In a separate mechanism for promoting motility in breast cancer cells, EphA2 internalization by MT1-MMP-dependent cleavage enhanced RhoA signaling leading to collapse of cytoskeletal architecture, cell rounding, and single-cell migration. This migratory phenotype also depended on a serine 897 residue present on the EphA2 cytoplasmic tail, a site directly phosphorylated by Akt in the absence of ephrin binding. EphA2 and Akt signaling may also intersect in normal mammary epithelial development since loss of Akt1 and Akt2 in mice disrupted expansion of the epithelial mammary tree during pregnancy and lactation similar to EphA2 loss.

The deregulation of EphB and ephrin-B signaling also contributes to breast cancer phenotypes. Specifically, lack of ephrin-B reverse signaling was associated with breast cancer progression by interfering with proper development of the mammary gland. Generation of transgenic mice expressing a C-terminal truncation mutant of ephrin-B2 driven by the mouse mammary tumor virus-long-terminal repeat (MMTV-LTR) promoter, which induces expression of mutant ephrin-B2 specifically in the mammary gland, disrupted development and correlated with increased primary tumor formation and lung or liver metastasis. In contrast, expression of full-length ephrin-B2 did not alter tumor latency and only modestly induced lung metastasis. Similar to the ephrin-B2-null phenotype, mice bearing ephrin-B2 cytoplasmic tail mutations showed marked reduction in the expression of E-cadherin and an increase in nuclear β-catenin in breast epithelial-derived tumors. Furthermore, ectopic expression of EphB4 disrupted proper mammary gland involution following lactation and resulted in enhanced breast cancer stem cell growth, decreased tumor latency, and the presence of lung metastases in MMTV-LTR-neu/T/ephB4 double transgenic mice but not in MMTV-LTR-ephB4 transgenic mice. These results indicate that overexpression of EphB4 potentiates the action of oncogenes such as HER2 (neu) during breast cancer progression. Additionally, EphB4 was shown to be a key regulator of oncogenic phenotypes in breast cancer cells since its loss or inhibition reduced survival, anti-apoptotic proteins, migration, invasion, tumor size, and vascularity. In the breast carcinoma cell lines tested, robust expression of EphB4 correlated with little to no detection of its cognate ligand, ephrin-B2. When ligand-induced receptor activation was restored with recombinant ephrin-B2, there was a significant decrease in cell survival. Cumulatively, these results suggest that gain of ligand independent EphB4 signaling combined with loss of ephrin-B2 reverse signaling facilitates breast cancer progression.

Additional Eph receptors have also been shown to be altered in breast cancer, including EphA4, EphA7, EphB4 and EphB6, which were significantly correlated with decreased overall survival and invasive ductal carcinoma. Epigenetic repression of EphA5 was associated with predictors of poor prognoses including high tumor grade, lymph node metastasis, and progesterone receptor negative status indicative of resistance to endocrine therapy. A genome-wide association study of more than 2,000 invasive breast cancer samples and matched controls revealed changes in EphB1, EphA3, and EphA7. This study proposed that Eph receptors serve as “driver kinases” that are somatically mutated in breast cancer.

Overall, Eph receptor and ephrin signaling contributes to normal mammary gland development but deregulation of this signaling axis can promote tumorigenesis in breast epithelial cells. Specifically, ligand-independent Eph receptor signaling and reverse signaling through ephrins appears to play a key role in mediating aggressive breast cancer phenotypes with poor clinical prognoses.

**Eph Receptors and Ephrins in Gut Epithelium**

**Eph receptor and ephrin expression in the gastrointestinal tract**

The single-layered, mucosal epithelium lining the gut has a high turnover rate that depends on the activity of stem cells located within specific compartments of its crypt-villous structure. In particular, stem cells are present at the bottom of crypts and divide asymmetrically to maintain self-renewal and produce a population of rapidly proliferating progeny. These transient amplifying cells ultimately give rise to differentiated cells along the crypt-villus axis as well as terminally differentiated Paneth cells in the base of the crypt. Interaction between intestinal epithelial stem cells and their daughter cells are important for the maintenance of this stem cell niche.

Human intestinal epithelium contain mRNA transcripts for the majority of Eph receptor and ephrin family members and a few of these have been directly implicated in intestinal epithelial homeostasis. The general expression pattern of Eph receptors and ephrins is relatively similar in the mucosal epithelium of the small and large intestines. In particular, EphB2 and EphB3 expression is concentrated in the cells that populate the crypt nadirs and decreases toward the top of the villi. Ephrin-B1 and ephrin-B2 are expressed in an inverse manner along villi with highest expression at the apices. This reciprocal gradient of receptor and ligand expression reflects a functional transition zone between proliferative and differentiated epithelial cell compartments within the intestine (Fig. 2). EphA receptors and...
ephrin-A ligands are also differentially expressed along the crypt-villous axis. For example, EphA1 is found in crypts while EphA2 and ephrin-A1 are present at the top of villi.\textsuperscript{91} However, a role for EphA and ephrin-A signaling in intestinal epithelial development or architecture has yet to be reported.

Regulation of Eph receptor and ephrin expression in the gut is dependent on several key signaling pathways. In particular, Wnt/β-catenin signaling is required for the maintenance of intestinal epithelial stem cells in crypts and targets EphB receptor gene expression by T-cell specific transcription factor (TCF)/β-catenin complexes.\textsuperscript{95,95,96} Accordingly, inhibition of TCF/β-catenin-mediated transcription by a dominant-negative TCF factor induced a loss of EphB2 and EphB3 mRNA transcripts while ephrin-B1 mRNA was up-regulated in colorectal cancer cells.\textsuperscript{97} Krüppel-like factor 5 (KLF5) has also been implicated in the positive regulation of EphB3 expression in the intestinal epithelium.\textsuperscript{98} Intestinal-specific loss of KLF5 led to reduction in EphB3 and ephrin-B1 expression coincident with severely compromised intestinal crypt architecture and barrier function. This intestinal epithelial defect may stem from aberrant β-catenin signaling as intestine-specific deletion of KLF5 further led to the loss of β-catenin nuclear localization. Transforming growth factor β signaling plays a critical role in wound healing responses of the intestinal mucosal epithelium in a manner that depends somewhat on Smad3-mediated induction of EphB2 and EphB3.\textsuperscript{99,100} EphB expression in colonic crypts by Smad3 accelerated re-epithelialization by regulating proliferation of intestinal epithelial cells. Hence, loss of EphB expression may account for some of the wound healing defects reported in the intestinal epithelium of Smad3 knockout mice.\textsuperscript{101} While EphA receptors and ephrin-A ligands are present in the gut, very little is known about how they are regulated in this tissue.

Eph receptor and ephrin function in gut epithelial homeostasis

EphB receptors and ephrin-B ligands have emerged as major regulators of intestinal crypt architecture.\textsuperscript{92,102} In particular, EphB and ephrin-B signaling is required for positioning and differentiation of intestinal epithelial cells as they transit along the crypt-villous axis. Ablation of EphB signaling in EphB2 and EphB3 double knockout mice decreased progenitor cell proliferation by limiting cell cycle reentry in intestinal crypts. This modification of the progenitor proliferative zone led to altered distribution of cells along intestinal crypts. These findings suggest that differential expression of EphB receptors and ephrin-B ligands provides a contextual cue that maintains the organization of progenitor and differentiated cell compartments in intestinal epithelium.\textsuperscript{92}

Sorting of EphB and ephrin-B expressing cells in the intestinal epithelium was shown to be driven by cell-cell repulsion events through destabilization of E-cadherin.\textsuperscript{103} EphB-expressing cells in apposition with EphB-expressing cells recruit ADAM10 to cell-cell borders where it cleaves E-cadherin and disrupts adherens junctions. Destabilization of cell-cell adhesion complexes limits intermingling of EphB- and ephrin-B-expressing cell populations, providing a putative molecular mechanism for maintaining epithelial cell compartments in the intestine. In support of this model, loss of ADAM10 in Paneth cells resulted in their improper positioning along the crypt axis.\textsuperscript{103} This phenotype was also seen following loss of EphB2.\textsuperscript{104} Interestingly, EphB2 appears to function in a kinase-dependent or -independent manner with distinct biological outcomes in the gut. Kinase-dependent signaling of EphB2 promoted cell cycle entry and proliferation in intestinal crypt progenitor cells, at least in part, through modulation of cyclin-D1 levels and Akt kinase activity.\textsuperscript{104} In contrast, the ability of EphB2 to maintain stem cell compartments was kinase-independent and reliant on phosphatidylinositol 3-kinase activity.\textsuperscript{104} Thus, EphB receptors and ephrin-B ligands help segregate progenitor and differentiated cell populations within the intestinal epithelium via modulation of adhesion complexes and downstream signaling pathways.

While EphA2 is not thought to be an essential regulator of intestinal morphogenesis, this RTK subtype may play a role in modulating barrier function in gut epithelium through destabilization of tight junctions.\textsuperscript{105} Activation of EphA2 with ephrin-A1 promoted interaction between the receptor and claudin-4, a tight junction-associated protein, in several epithelial cell lines including HT29 colon carcinoma cells.\textsuperscript{105} EphA2 led to claudin-4 phosphorylation and its mislocalization from cell-cell contacts coincident with an increase in paracellular permeability. The negative regulation of tight junctions by EphA2 was contrasted by the reinforcement of the tight junction barrier by ephrin-B1 which itself interacted with claudins-1 and -4 in HT29 cells.\textsuperscript{106} Thus, different Eph receptor and ephrin subclasses appear to have opposing effects on epithelial tight junction integrity and function in the gut.

As in the intestine, EphB receptors are concentrated in the crypt epithelium while ephrin-B ligands are prominently expressed in the upper villous regions of the stomach. Cells in the isthmus, the region connecting the gastric pits and gastric glands, proliferate and differentiate giving rise to distinct cell lineages that populate the gastric mucosal epithelium. The exact role of Eph receptors and ephrins in the upper regions of the human gastrointestinal tract remains largely unknown. However, EphB and ephrin-B signaling may be important in the transition between stratified squamous and simple columnar epithelium in the murine stomach. In particular, EphB2 is restricted to the junctional zone between these two epithelial compartments while ephrin-B1 occupies the stratified epithelial layers in the stomach.\textsuperscript{107,108} These findings support the notion that EphB and ephrin-B signaling provide cues in the cellular microenvironment that help orchestrate the organization of structurally and functionally distinct epithelial cell compartments within the gastrointestinal tract.

Eph receptor and ephrin signaling in gastrointestinal disease

As key regulators of intestinal homeostasis, abnormal EphB and ephrin-B expression is linked to malignant and diseased states in the gut.\textsuperscript{109,110} In the intestinal epithelium of patients with inflammatory bowel disease (IBD), there was a significant up-regulation of ephrin-B2 in lesions with little change in EphB expression.\textsuperscript{90} Treatment of rat intestinal epithelium cells with a
recombinant EphB1 ectodomain to stimulate ephrin-B reverse signaling enhanced scratch wound closure in vitro.90 These findings suggest that ephrin-B2 responds to EphB receptors in order to enhance intestinal epithelial repair and barrier function but it is also possible that ephrin-B2 functions in the absence of EphB receptor stimulation in the gut epithelium of IBD patients.

The complementary expression of EphB receptors and ephrin-B ligands is also perturbed in colorectal cancers. EphB2 and EphB3 are lost during colorectal cancer progression and the extent of down-regulation correlates with higher tumor grade.111 EphB receptor activation was positively associated with E-cadherin-mediated adhesion of colorectal cancer cells, which contributed to their segregation from cells expressing ephrin-B ligand.112 Interestingly, ephrin-B1 loss disrupted the organization of tumor cell compartments and accelerated growth of intestinal tumors that spontaneously develop in Apcmin/+ mice, which may be relevant to patients with hereditary human colorectal cancers with mutations in the adenomatous polyposis coli (APC) tumor suppressor gene.113,114 This study provided additional support for the idea that ephrins present within the tumor microenvironment can create repulsive cues to prohibit Eph receptor-expressing cancer cell growth and invasion.

EphA receptors are also deregulated in gastrointestinal malignancies. Expression of EphA1 and EphA2 is associated with poor prognosis in gastric cancer.15,116 Increased EphA1 expression significantly correlated with increased tumor grade and lymph node metastasis and decreased cumulative survival in gastric carcinomas. Ephrin-A1 mRNA transcripts independently predicted poor prognosis in colorectal cancer patients and knockdown of this ligand inhibited proliferation and migration of colon carcinoma cell lines.117 As in the mammary gland, EphA expression may synergize with oncogenic pathways to enhance cancer progression. Notably, EphA2 and ephrin-A1 differentially impact tumor burden in Apcmin/+ mice: ephrin-A1 promotes tumorigenesis while loss of EphA2 reduces tumor formation.118,119 It is therefore possible that an “Eph-switch” from B type to A type receptors contributes to the malignant transformation of gut epithelia.

Taken together, these data suggest an important role for Eph receptor and ephrin signaling in organizing epithelial stem cell compartments in the gastrointestinal tract through governance of proliferation in crypts and differentiation in villi. Loss of Eph receptor and ephrin signaling that disrupts intestinal epithelial stem cell compartments appears to render the gut more vulnerable to tumorigenic progression.

**Eph Receptors and Ephrins in Skin**

Eph receptor and ephrin expression in epidermis and hair follicles

The epidermis is composed of a stratified squamous epithelium that undergoes a specialized form of differentiation, termed keratinization. This constantly renewing epithelial tissue depends on progenitor cells in the basal layer to replace epidermal cells lost by desquamation or through injury in the more superficial layers.120 Keratinocytes are not only tightly anchored to their neighbors via junctional complexes but also directly exchange information with one another in a manner that controls their differentiation state.121 Recent studies indicate that Eph receptors and ephrins mediate cell-cell communication in the epidermis to regulate keratinocyte proliferation, migration, adhesion, differentiation, and survival.

While Eph receptors from both subclasses are present in the epidermis, the regulated expression EphA receptors in keratinocytes is somewhat more clear and varies with differentiation.122 In particular, EphA2 is prominently expressed by primary keratinocytes in culture but is markedly down-regulated upon differentiation in vitro.123 In contrast, EphA1 and EphA4 are abundantly expressed in cultured, differentiated keratinocytes and are also found in the suprabasal layers of the epidermis. Interestingly, ephrin-A1 is concentrated in the progenitor cell-containing basal layer of human epidermis (Fig. 2).124,125 This cellular localization pattern suggests that EphA receptors and ephrin-A ligands may play an important role as keratinocytes commit to a pathway of differentiation at the transition between the basal and suprabasal layers.

Several factors have been shown to regulate EphA and ephrin-A gene expression in the epidermis. For example, p63 is a master regulator of epidermal differentiation capable of increasing EphA1 and EphA4 mRNA levels via KLF4 induction, which reflects the suprabasal expression pattern of these RTK subtypes in vivo.124,125 In contrast, EphA2 levels are increased following activation of epidermal growth factor receptor in multiple cell types, including epidermal carcinoma cells; this might explain why receptor levels are kept low under homeostatic conditions in skin.126 Accordingly, inflammatory signals and environmental stress impact epidermal EphA2 expression as this receptor is upregulated in keratinocytes by several pro-inflammatory cytokines and ultraviolet radiation.125,127–129 Interestingly, a cluster of ephrin-A genes (EFNA1, EFNA3, EFNA4) exists on the q arm of chromosome 1 in an area proximal to the epidermal differentiation complex harboring several genes coordinately regulated during keratinization. While ephrin-A1 is a known target of tumor necrosis factor α (TNFα) signaling in many cell types, including keratinocytes, very little is known about what regulates expression of most other ephrins in the epidermis.127

The hair follicle is a skin appendage that is contiguous with the epidermis and undergoes continuous cycling through the stages of anagen (growth), catagen (death), and telogen (rest). This regeneration process relies on hair follicle stem cells located in the bulge region and the hair germ.120,130 Bulge stem cells also participate in the wound healing and repair of the interfollicular epidermis.131 EphA and EphB receptor subtypes are found in the hair follicle with EphA4, EphB4, ephrin-A3, and ephrin-B1 concentrated in the bulge region. Ephrin-A3 and ephrin-B2 are also found in the dermal papilla, a fibroblast-enriched stromal region important for hair follicle cycling events.132–135 Increased ephrin-A mRNA transcripts in mouse skin correlated with the onset of anagen with ephrin-A3 exhibiting the highest expression during this active growth phase.135 The regulated expression of Eph receptors and
Eph receptor and ephrin function in epidermal homeostasis

To a certain degree, epidermal homeostasis reflects a balance between cell proliferation in the basal layer and cell differentiation and death in the upper layers. Eph receptor and ephrin signaling is emerging as a major pathway that controls these aspects of epidermal homeostasis. For example, the extracellular signal-regulated kinase 1/2 (Erk1/2)-MAPK pathway supports keratinocyte proliferation and must be dampened to allow for cell cycle exit and differentiation. EphA2 acts in a ligand-dependent manner to attenuate Erk1/2 signaling in a variety of epithelial cells, including keratinocytes. A role for Eph receptor and ephrin signaling in epidermal growth control is further supported by the observation that injection of recombinant proteins containing ectodomain fragments of Eph receptors or ephrin ligands increased keratinocyte proliferation in the epidermis and hair follicles. While Eph receptor and ephrin signaling likely serve to limit keratinocyte proliferation, these RTKs may also play a role in cell survival pathways to eliminate keratinocytes damaged by environmental insults. In particular, EphA2 is up-regulated in keratinocytes following UV radiation and was required for apoptosis.

Ephrin-A ligands appear to be particularly important for eliciting differentiation in keratinocytes, at least in cell culture models. In particular, delivery of soluble ephrin-A ligand to keratinocyte stratification and differentiation. Specifically, ephrin-A1-mediated activation of EphA2 induced the expression of the desmosomal cadherin desmoglein 1, which was required for strengthening of cell-cell adhesion and robust differentiation. While desmoglein 1 induction represents a major signaling node for efficient execution of a keratinocyte differentiation program, ephrin action in the epidermis is likely to be more complex. Accordingly, the profiling of genes regulated by ephrin-A ligands in epidermal keratinocytes revealed targets not only involved in adhesion and differentiation but also proliferation, migration, and proteolysis. These studies uncovered subsets of genes that were similarly regulated by ephrin-A3, ephrin -4, and ephrin -5 while ephrin-A1 and ephrin-A2 gene targets were somewhat distinct, highlighting non-redundant roles for the various ephrin members in the epidermis.

Interestingly, reverse signaling via ephrin-B ligands in keratinocytes can also induce differentiation and restrict migration. Treatment of keratinocytes with EphB2-Fc fusion dimers to stimulate ephrin-B ligands led to an upregulation of genes related to differentiation and coincided with a loss of integrins and cell cycle regulators. While ephrin-B2 appears to be dispensable in the mouse epidermis, there is a role for dermal ephrin-B2 during the perinatal period of mice through indirect control of keratinocyte proliferation in the basal layer. Thus, Eph receptor and ephrin signaling seem to generally provide information about the cellular microenvironment that supports epidermal differentiation even though the specific signaling effectors are likely to vary among receptor and ligand subclasses.

Eph receptor and ephrin signaling in skin disease

Eph/ephrin signaling has been associated with a variety of human skin diseases, including nonmelanoma skin cancers and psoriasis. For example, the epidermis of psoriatic lesions is characterized by hyperplastic keratinocytes that poorly differentiate, leading to the formation of thick, scaly plaques. These lesions show a marked increase in EphA2 levels coincident with a reduction in ephrin-A1 and ephrin-A3 expression. Similarly, EphA2 was increased by a variety of growth factors and pro-inflammatory cytokines, including epidermal growth factor, interleukin-1α and TNFα, in a 3-dimensional organotypic culture model of human epidermis. Interestingly, targeting of EphA2 for activation and subsequent downregulation with recombinant ephrin-A1 ligand was capable of normalizing keratinocyte differentiation in this human skin culture model of inflammation. Thus, ephrin-A1 delivery may ultimately prove effective in resolving lesions of patients with psoriasis when combined with treatments that target inflammation.

EphA receptors also serve as tumor suppressors in the skin. In particular, deletion of EphA2 in mice led to significantly enhanced susceptibility to 2-stage skin carcinogenesis resulting in increased tumor size, number, and invasiveness. The highly related EphA1 receptor has also been implicated as a tumor suppressor in skin. Loss of EphA1 expression is associated with poorly differentiated basal and squamous cell carcinomas although the specific role of this particular RTK in normal or transformed keratinocytes remains largely unexplored. Moreover, the consequence of ephrin-A ligand loss for skin carcinogenesis merits additional investigation. Defining specific roles for Eph receptor and ephrin signaling complexes in skin will likely reveal pathways that can normalize keratinocyte behavior in disease states such as cancer and psoriasis.

Conclusion

A growing body of work has revealed key roles for Eph receptors and ephrins in the maintenance of epithelial tissue homeostasis, particularly in the breast, gut, and skin. As mediators of a diverse set of epithelial cell responses that impact proliferation, migration, differentiation, survival, and the organization of stem cell compartments, Eph receptors and ephrins must be tightly regulated to prevent their possible contributions to epithelial-derived diseases. Understanding the genetic and epigenetic regulation of these receptors and ligands in epithelial tissues remains an area to be more fully explored and an important hurdle to clear as the expression of Eph receptors and ephrins appears to be organ- and tissue-specific with extensive post-translational control of their cellular levels.

Eph receptors and ephrins represent a large family of signaling proteins that can operate in concert or independent of one another. Functional redundancy and combinatorial interactions between receptor and ligand increases the complexity
of their signaling potential; this can complicate interpretation of studies aimed at defining specific roles for Eph receptors and ephrins in epithelial tissue homeostasis. As Eph receptor and ephrin-mediated cell-cell communication is altered in most epithelial-derived cancers, it will be important to elucidate the context-specific signal transduction pathways elicited by Eph receptors and ephrins in various epithelia. Ultimately, Eph receptors and ephrins serve as attractive pharmacological targets for disease as downstream signaling pathways impacted by these surface receptor-ligand complexes help maintain epithelial tissue homeostasis.

References

1. Gale NW, Holland SJ, Valenzuela DM, Flenникen A, Pan L, Ryan TE, Henkmeyer M, Strehblow H, Hirai H, Wilkinson DG, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996; 16:17-9; PMID:8755476; http://dx.doi.org/10.1016/0896-6273(96)00276-7

2. Eph Nomenclature Committee. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 1998; 95:403-4; PMID:9627020; http://dx.doi.org/10.1016/S0092-8674(00)80580-0

3. Himanen JP, Chumley MJ, Lademann M, Li C, Barton WA, Jeffrey PD, Vearing C, Geleck D, Feldheim DA, Boyd AW, et al. Repelling class discrimination: ephrin-A5 to-α and activates EphB2 receptor signaling. Nat Neurosci 2004; 7:50-9; PMID:15107857; http://dx.doi.org/10.1038/nn1237

4. Alford S, Watson-Hurthig A, Scott N, Carette A, Lorimer H, Bazowski J, Howard PL. Soluble ephrin B1 is required for the growth of Hela and SK-BR3 cells. Cancer Cell Int 2010; 10:1475-2667; http://dx.doi.org/10.1186/1475-2861-10-1.0

5. Beauchamp A, Lively MO, Minz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteinases. Mol Cell Biol 2012; 32:5253-64; PMID:22688511; http://dx.doi.org/10.1128/MCB.00791-11

6. Himanen JP, Verrymekayaev J, Lames PW, Walker JR, Xu K, Atapattu L, Neve RM, Das D, Gray JW, Groves JT. Restriction of receptor movement alters cellular response: physical force sensing by EphA2. J Biol Chem 2011; 286:21611-6; PMID:21801264; http://dx.doi.org/10.1074/jbc.2010.10.005

7. Jans PW, Nievengg E, Lackmann M. Concepts and consequences of Eph receptor clustering. Semin Cell Dev Biol 2012; 23:43-50; PMID:22621642; http://dx.doi.org/10.1016/j.semcdb.2012.01.001

8. Singh A, Winterboener E, Dar AO. Ephrin signaling in cell-cell and cell-substrate adhesion. Front Biosci 2012; 17:473-97; http://dx.doi.org/10.2741/3939

9. Coulthard MG, Morgan M, Woodruff TM, Arumugam M, Nievengg E, Lackmann M. Concepts and consequences of Eph receptor clustering. Semin Cell Dev Biol 2012; 23:43-50; PMID:22621642; http://dx.doi.org/10.1016/j.semcdb.2012.01.001

10. Merlos-Suarez A, Batlle E. Eph-ephrin signaling in epithelial development and homeostasis. Int J Biochem Cell Biol 2009; 41:561-70; PMID:18754422; http://dx.doi.org/10.1016/j.biocel.2008.07.019

11. Gucciardo E, Sugiyama N, Lethi K. Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics. Cell Mol Life Sci 2014; 4:4.

12. Lim S, Wang B, Geno A. Ephrin signaling in epithelial development and homeostasis. Cell Adh Migr 2012; 6:126-30; PMID:23021982; http://dx.doi.org/10.1007/s10555-012-9352-1

13. Friese J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

14. Ivanov AL, Romanovsky AA. Putative dual role of ephrin-Eph receptor interactions in inflammation. JUWBM Life 2006; 58:389-94; PMID:16801213; http://dx.doi.org/10.1016/j.jubmr.2006.07.004

15. Arvanitis D, Dey A. Eph signaling: networks. Genes Dev 2008; 22:2146-29; PMID:18281458; http://dx.doi.org/10.1101/gad.1630480

16. Mao H, Wang B. Ephrin signaling in epithelial development and homeostasis. Int J Biochem Cell Biol 2009; 41:561-70; PMID:18754422; http://dx.doi.org/10.1016/j.biocel.2008.07.019

17. Friese J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

18. Coulthard MG, Morgan M, Woodruff TM, Arumugam M, Nikolov D, Lackmann M, Zisch AH, Kalo MS, Chong LD, Janes PW, et al. Architecture of Eph family receptors and their ligands, the ephrins. IUBMB Life 2006; 58:389-94; PMID:16801213; http://dx.doi.org/10.1016/j.iubmb.2006.07.004

19. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

20. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

21. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

22. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

23. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

24. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

25. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

26. Frisen J, Barbacid M. Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell Tissue Res 1997; 290:209-15; PMID:9321682; http://dx.doi.org/10.1007/BF00061055

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Funding

This work was supported in part by a grant to SG (AR062110) and a Core Center grant to Northwestern University (Skin Disease Research Center, AR057216) from the National Institutes of Health (NIH). BEPW was supported by an NIH-T32 training program fellowship (AR060710).

www.landesbioscience.com  Cell Adhesion & Migration  335
47. Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Teng SW, Neel BG, Bastiaens PI, Lackmann M. PTP1B to rule them all? One raft to sort them? One raft to dominate? J Cell Biol 2008; 10:1035-43; PMID:19160501; http://dx.doi.org/10.1083/jcb.20070909.

48. Nikolova Z, Djonov V, Zuercher G, Andres AC, Ziegler F. A cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrinB2 during mammary gland morphogenesis. J Cell Biol 2005; 8:845-56; PMID:18081806; http://dx.doi.org/10.1083/jcb.200507026.

49. Kornos-Mehr H, Web Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn 2006; 235:3404-12; PMID:17099550; http://dx.doi.org/10.1002/dvdy.20978.

50. Kouros-Mehr H, Werb Z. Candidate regulators of epithelial cell death at lactation. Dev Growth Differ 2002; 44:257-65; PMID:12496371; http://dx.doi.org/10.1002/dvdy.100551.

51. Kim J, Lee H, Kim Y, Yoo S, Park E, Park S. The SAM domain of GPR52 recruits HGF-induced epithelial cell survival by activating Akt. Dev Dyn 2009; 51:809-19; PMID:19843150; http://dx.doi.org/10.1002/dvdy.20978.

52. Kaenel P, Hahnweald S, Wotzkow C, Strange R, Andres AC. Overexpression of EphB4 in the mammary epithelial stem cells predisposes a pathway of progenitor cells and promotes branching activity and vascularization. Dev Growth Differ 2014; 56:255-75; PMID:24635767; http://dx.doi.org/10.1111/dgd.12126.

53. Teng SW, Neel BG, Bastiaens PI, Lackmann M. PTP1B to rule them all? One raft to sort them? One raft to dominate? J Cell Biol 2008; 10:1035-43; PMID:19160501; http://dx.doi.org/10.1083/jcb.20070909.

54. Fox BP, Kandpal RP. Invasiveness of breast carcinoma cells and transfact script: EPB and ephrin ligands as molecular markers of potential diagnostic and therapeutic application. Biochim Biophys Acta 2002; 1588:82-93; PMID:12047954; http://dx.doi.org/10.1016/S0005-2760(02)00087-5.

55. Kouros-Mehr H, Web Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn 2006; 235:3404-12; PMID:17099550; http://dx.doi.org/10.1002/dvdy.20978.

56. Kouros-Mehr H, Werb Z. Candidate regulators of epithelial cell death at lactation. Dev Growth Differ 2002; 44:257-65; PMID:12496371; http://dx.doi.org/10.1002/dvdy.100551.

57. Nikolova Z, Djonov V, Zuercher G, Andres AC, Ziegler F. A cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrinB2 during mammary gland morphogenesis. J Cell Biol 2005; 8:845-56; PMID:18081806; http://dx.doi.org/10.1083/jcb.200507026.

58. Zelinski DP, Zandt ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61:2380-8; PMID:11379305; http://dx.doi.org/10.1158/0008-5472.CAN-00-070.

59. Lu M, Miller KD, Gokmen-Polar Y, Engel M, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res 2003; 63:3429-35; PMID:12889683.

60. Zhang G, Brndicky-Seidel DM, Vaughn D, Yu J, Xie L, Wells S, Jackson D, Murasoka-Cook R, Arteaga C, Chen J. Elevierung of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010; 70:239-308; PMID:20288874; http://dx.doi.org/10.1158/0008-5472.CAN-09-1845.

61. Fang WB, Ierton RC, Zhang G, Takahashi T, Reynolds JF. Overexpression of EphA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci 2011; 201:2034-45; PMID:21635095; http://dx.doi.org/10.1242/jcs.076042.

62. Papaxoinis K, Triantafyllou K, Sasco AJ, Nicolopoulos L, Gerakopoulou EK, Papageorgiou A, Aroni P, Hatzis P, Vassilakos P. Subsite-specific differences in eph-related receptor protein tyrosine kinases in mammary gland epithelial differentiation pathway. Int J Oncol 2012; 40:567-75; PMID:22208958; http://dx.doi.org/10.3892/ijo.2011.1907.

63. Weiler S, Rohrbach V, Pulvirenti T, Adams R, Zieske A, Walter-Sack S, Wunderlich K, Pfeifer M, Linker T, Vogel S, Weidner N, Zurcher G, Andres AC. Overexpression of EphB4 in the mammary epithelial stem cells predisposes a pathway of progenitor cells and promotes branching activity and vascularization. Dev Growth Differ 2014; 56:255-75; PMID:24635767; http://dx.doi.org/10.1111/dgd.12126.

64. Miao H, Nickel CH, Canley LG, Bruckheimer E, Kinch MS, Miller KD. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ERE(2) positive breast cancer. Breast Cancer Res 2011; 13:257-64; PMID:20602615; http://dx.doi.org/10.1054/jb.2010.1004-04.

65. Andres AC, Reid HH, Zurcher G, Blaschke RJ, Albrecht D, Ziemiecki A. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene 1994; 9:1461-7; PMID:8152808.

66. Hoffman EE, Farooqui N, Khan Y, Staal J, Boffa K, Bruckheimer E, Kinch MS, Miller KD. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. J Biol Chem 2007; 282:10625-33; PMID:17103707; http://dx.doi.org/10.1074/jbc.M608509200.

67. Kaenel P, Hahnweald S, Wotzkow C, Strange R, Andres AC. Overexpression of EphB4 in the mammary epithelial stem cells predisposes a pathway of progenitor cells and promotes branching activity and vascularization. Dev Growth Differ 2014; 56:255-75; PMID:24635767; http://dx.doi.org/10.1111/dgd.12126.

68. Brindley-Sieders DM, Jiang A, Sarma K, Bade DC, Weidner N, Zurcher G, Andres AC. Overexpression of EphB4 in the mammary epithelial stem cells predisposes a pathway of progenitor cells and promotes branching activity and vascularization. Dev Growth Differ 2014; 56:255-75; PMID:24635767; http://dx.doi.org/10.1111/dgd.12126.

69. Chen CC, Boxer RB, Stairs DB, Fortecaro CP, Horton RH, Alvarez JV, Bernbaum MJ, Chodosh LA. Akr is required for Star5 activation and mammary
93. Batlle E, Henderson JT, Beghtel H, van den Born AC. Deregulated EphB4 and ephrin-B2 expression in the mammary gland interfaces with the development of both the glandular epithelium and vasculature and promotes metastasis formation. Int J Oncol 2009; 35:525-36; PMID:19639173

92. Knees J, Jung K, Jochymski K, Worckow C, Andres AC. Preponderance of death cell stem cell characteristics in metastasising mouse mammary tumours induced by deregulated EphB4 and ephrin-B2 expression. Cell Adhesion Migr 2010; 14:215-27; doi.org/10.1007/s10404-010-0155-z

91. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui MM, Sancho E, Verweij C, de Lau W, Oving J, Harlizius A, van der Horst K, Batlle E, Cou垂re D, Haramis AP, et al. The β-pacinian-TFC4 complex imposes a progenitor phenotypic on colorectal cancer cells. Cell 2002; 111:241-50; PMID:12408869 http://dx.doi.org/10.1002/cct.10122

90. Hafner C, Meyer S, Langmann T, Schmitz G, Bataille WY, Chan TL, Mifflin RC, Powell DW, Yuen ST, Elder JT, et al. Ephrin-B2 is differentially expressed in the intestinal stem cell niche. Cell 2002; 111:251-63; PMID:12408865 http://dx.doi.org/10.1016/S0092-8674(02)01012-1

89. Batlle E, Bacani J, Beghtel H, Jonkheer S, Gregoire S, van de Bult M, van den Born AC. EphB4 as tumor promoter and suppressor regulated survival factor in breast cancer. Am J Pathol 2006; 169:1071-82; PMID:16847593 http://dx.doi.org/10.1016/j.ajpath.2006.04.030

88. Batlle E, Bacani J, Beghtel H, Jonkheer S, Gregoire S, van de Bult M, van den Born AC. EphB4 and ephrin-B2 ligands are coexpressed in epithelial malignancies. Histochem Cell Biol 2011; 136:617-36; PMID:21276341 http://dx.doi.org/10.1007/s00343-010-3479-x

87. Bonifaci N, Gorski B, Masojc B, Wokolorczyk D, Genander M, Halford MM, Xu NJ, Eriksson M, Yu H, Bucana CD, Ellis LM. Coexpression of ephrin-Bs and EphB receptors in colorectal cancer. Int J Cancer 2010; 126:2003-11; PMID:20039322 http://dx.doi.org/10.1002/ijc.25147

86. Fu DY, Wang ZM, Wang BL, Chen L, Yang WT, Wang YW, Chan TL, Mifflin RC, Powell DW, Yuen ST, Elder JT, et al. EphB4 receptor activity suppresses colorectal cancer progression. Nature 2005; 435:1126-30; PMID:15973414 http://dx.doi.org/10.1038/nature03626

85. Cortsina P, Palomo-Ponce S, Iglesias M, Fernandez-Manjón J, Benito EM, Whissell G, Huma M, Peiro N, Gallego I, Jonkheer S, et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalising tumour cells. Nat Genet 2007; 39:376-83; PMID:17986625; http://dx.doi.org/10.1038/ng.2007.11

84. Courtes C, Hendriks L, Dekker J, Ploegh HL. EphB2/ephrin-B2 signaling in stem cells. Biochim Biophys Acta 2013; 2:160031; doi.org/10.1016/j.bbrc.2011.01.045

83. Kaenel P, Schwab C, Mulchi K, Wotzkow C, Andres H, Haldimann M, Custer D, Munarini N, Stirnimann C, Jung K, Beghtel H, van den Born AC. Live and let die in the epithelial-mesenchymal transition axis in psoriatic epidermis. J Invest Dermatol 2013; 140:659-75; PMID:23881165; http://doi.org/10.1016/j.jid.2013.01.1129-2

82. Liu W, Ahmad SA, Jung YD, Reimuth N, Fan B, Bucana CD, Ellis LM. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002; 94:934-9; PMID:11924061 http://dx.doi.org/10.1002/cncr.10122

81. Hrath NI, Boyd AW. The role of Eph receptors and ephrin ligands in colorectal cancer. Int J Cancer 2010; 126:2003-11; PMID:20039322 http://dx.doi.org/10.1002/ijc.25147

80. Battle E, Bacani J, Beghtel H, Jonkheer S, Georgiev A, van de Bult M, Malaz N, Sancho E, Boon E, Powell DW, Yuen ST, Elder JT, et al. Alteration of the EphA2Ephrin-A signaling axis in psoriatic epidermis. J Invest Dermatol 2010; 139:679-92
124. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev 2006; 20:3185-97; PMID:1714587; http://dx.doi.org/10.1101/gad.1463206

125. Sen GL, Boxer LD, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced apoptosis. Mol Biol Cell 2012; 22:669-77; PMID:22364861; http://dx.doi.org/10.1016/j.devel.2011.12.001

126. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced apoptosis. Mol Biol Cell 2012; 22:669-77; PMID:22364861; http://dx.doi.org/10.1016/j.devel.2011.12.001

127. Banno T, Gazel A, Blumenberg M. Pathway-specific effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004; 279:32633-42; PMID:15145954; http://dx.doi.org/10.1074/jbc.M400642200

128. Banno T, Gazel A, Blumenberg M. Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem 2005; 280:18973-80. Epub 2005 Feb 18; PMID:15722350; http://dx.doi.org/10.1074/jbc.M411758200

129. Zhang G, Njauw CN, Park JM, Naruse C, Asano M, Tsao H. EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res 2008; 68:1691-6; PMID:18399848; http://dx.doi.org/10.1158/0008-5472.CAN-07-2372

130. Lavker RM, Sun TT, Oshima H, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev 2006; 20:2137-45; PMID:16849550; http://dx.doi.org/10.1016/j.devel.2011.12.001

131. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol 2009; 10:207-17; PMID:19209183; http://dx.doi.org/10.1038/nrm2636

132. Midorikawa T, Chikazawa T, Yoshino T, Takada K, Arase S. Different gene expression profile observed in dermal papilla cells related to androgenic alopecia by DNA microarray analysis. J Dermatol Sci 2004; 36:25-32; PMID:15488702; http://dx.doi.org/10.1016/j.jdermsci.2004.05.001

133. Egawa G, Osawa M, Uemura A, Miyachi Y, Nishikawa M, Akiyama M, Ferraris C, Chevalier G, Favier B, Jahoda CA, Dhouailly D, et al. Hair follicle stem cells. J Invest Dermatol Symp Proc 2003; 8:28-38; PMID:12894992; http://dx.doi.org/10.1046/j.1523-1747.2003.12169.x

134. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, Fuchs E. Defining the epithelial stem cell niche increases the density of hair follicles but also accelerates anagen development in neonatal mice. J Cell Biol 2009; 185:1243-58; PMID:19546243; http://dx.doi.org/10.1083/jcb.200809043

135. Yamada Y, Midorikawa T, Oura H, Yoshino T, Ohadera M, Kubo Y, Arase S. Ephrin-A3 not only increases the density of hair follicles but also accelerates anagen development in neonatal mice. J Dermatol Sci 2008; 52:178-85; PMID:18640411; http://dx.doi.org/10.1016/j.jdermsci.2008.05.007

136. Dumesic PA, Scholl FA, Barragan DI, Khavari PA. Erk12 MAP kinases are required for epidermal G2M progression. J Cell Biol 2009; 185:409-22; PMID:19414607; http://dx.doi.org/10.1083/jcb.200804038

137. Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, Wang B. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006; 66:7050-8; PMID:16849550; http://dx.doi.org/10.1158/0008-5472.CAN-06-0004

138. Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, Hsieh JT, Page P, Liu L, Lindner DJ, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One 2012; 7:15; http://dx.doi.org/10.1371/journal.pone.0042120

139. Lema Tome CM, Palma E, Ferluga S, Lowther WT, Hanigan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem 2012; 287:14012-22; PMID:22362770; http://dx.doi.org/10.1074/jbc.M111.311670

140. Zarnegar BJ, Johnston D, Siprashvili Z, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev 2009; 23:2070-81; PMID:19571816; http://dx.doi.org/10.1016/j.devcel.2011.12.001

141. Lin S, Gordon K, Kaplan N, Getsios S. Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1. Mol Biol Cell 2010; 21:3902-14; PMID:20861311; http://dx.doi.org/10.1091/mbc.E10-03-0042

142. Getsios S, Simpson CL, Koijima S, Harmon R, Sheu LJ, Dueck RL, Corrwell M, Green KJ. Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis. J Cell Biol 2009; 185:1243-58; PMID:19546243; http://dx.doi.org/10.1083/jcb.200809044

143. Walsh R, Blumenberg M. Specific and shared targets of ephrin A signaling in epidermal keratinocytes. J Biol Chem 2011; 286:9419-28; PMID:21933931; http://dx.doi.org/10.1074/jbc.M110.197087

144. Walsh R, Blumenberg M. Eph-2B, acting as an extracellular ligand, induces differentiation markers in epidermal keratinocytes. J Cell Physiol 2012; 227:2330-40; PMID:22809346; http://dx.doi.org/10.1002/jcp.22968